Nevena Damjanov, MD
Professor of Clinical Medicine (Hematology-Oncology)
Attending Physician, Penn Presbyterian Medical Center
Attending Physician, Hospital of the University of Pennsylvania
Director of GI Oncology, Abramson Cancer Center at the Penn Presbyterian Medical Center
Attending Physician, Corporal Michael Crescenz VA Medical Center
Section Chief, Hematology-Oncology, Corporal Michael Crescenz VA Medical Center
Department: Medicine
Contact information
Penn Presbyterian Medical Center
51 North 39th Street
220 MOB
Philadelphia, PA 19104
51 North 39th Street
220 MOB
Philadelphia, PA 19104
Office: 215-662-8488
Fax: 215-243-3249
Fax: 215-243-3249
Education:
BA (Biology, Philosophy)
University of Pennsylvania, 1985.
MD (Internal Medicine)
Hahnemann University, 1989.
CTF (Leading Success)
Raymond and Ruth Perelman School of Medicine University of Pennsylvania, 2015.
Permanent linkBA (Biology, Philosophy)
University of Pennsylvania, 1985.
MD (Internal Medicine)
Hahnemann University, 1989.
CTF (Leading Success)
Raymond and Ruth Perelman School of Medicine University of Pennsylvania, 2015.
Selected Publications
Sony Tuteja, Mari Cayabyab, Glenda Hoffecker, Lisa A. Varughese, Jean De Dieu. Ndayishimiye, Victoria Wittner, Xingmei Wang, Margaret Harr, Avni Santani, Hakon Hakonarson, Ryan Massa, Nevena Damjanov, Nandi Reddy, Randy Oyer, Ursina R. Teitelbaum: Implementing DPYD/UGT1A1 testing to prevent treatment related adverse events (TRAE) in patients with gastrointestinal (GI) cancer: results of a pragmatic implementation trial. J Clin Oncol May 2024.Sony Tuteja, Mari Cayabyab, Glenda Hoffecker, Lisa A. Varughese, Jean D. Ndayishimiye, Victoria Wittner, Xingmei Wang, Rachel Hatch, Donna Capozzi, Margaret Harr, Avni Santani, Hakon Hakonarson, Ryan Massa, Nevena Damjanov, Nandi Reddy, Randy Oyer, Ursina R. Teitelbaum: Implementing DPYD/UGT1A1 testing to prevent treatment related adverse events (TRAEs) in patients with gastrointestinal (GI) cancer: results of a pragmatic implementation trial. ClinPGx 2024: Knowledge, Implementation & Education 2024.
Michael C. Soulen, Ursina R. Teitelbaum, Rosemarie Mick, Jennifer Eads, Jeffrey I. Mondschein, Mandeep Dagli, Diana van Houten, Nevena Damjanov, Charles Schneider, Keith Cengel, David C. Metz : Integrated capecitabine-temozolomide with radioembolization for liver-dominant G2 NETs: long-term outcomes of a single-institution retrospective study. CardioVascular and Interventional Radiology December 2023.
Jeffrey W. Shevach, MD, Lisa B. Aiello, PhD, RN, AOCNS, Julie A. Lynch, PhD, RN, MBA , Jeffrey Petersen, MD, Lori Hoffman-Hogg, MS, RN, CNS, AOCN, Deborah Hartzfeld, MS, Margaret Lundquist, DNP, MPH, CRNP, Michael J. Kelley, MD, Maren T. Scheuner, MD, MPH , Robert Montgomery, MD Nevena Damjanov, MD Kyle Robinson, MD, Yu-Ning Wong, MD, Darshana Jhala, MD, Ravi B. Parikh, MD, MPH, and Kara N. Maxwell, MD, PhD: On-Site Nurse-Led Cancer Genetics Program Increases Cancer Genetic Testing Completion in Black Veterans. JCO Oncology Practice 19(8), May 2023.
Damjanov, N: Clinical Edge Journal Scan Commentary: HCC MDEdge December 2022.
Damjanov, N: Clinical Edge Journal Scan Commentary: HCC MDEdge November 2022.
Damjanov, N: Clinical Edge Journal Scan Commentary: HCC MDEdge October 2022.
M. Borad, M. Javle, W. Shaib, K. Mody, F. Bergamo, W. Harris, N. Damjanov, T. Macarulla, G. Brandi, G. Masi, M. Droz dit Busset, A. Boncompagni, M. Dimova-Dobreva, M. Engelhardt, M. Saulay, T. Halfdanarson, J. Knox, G. Abou-Alfa, N. Personeni, V. Mazzaferro: Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications. Ann Oncol September 2022.
Damjanov, N: Clinical Edge Journal Scan Commentary: HCC MDEdge September 2022.
Damjanov, N: Clinical Edge Journal Scan Commentary: HCC MDEdge August 2022.